ProCE Banner Activity

CME

Expanding the Scope of Precision Care for Patients With HR-Positive Breast Cancers: Things You Should Know

Multimedia
In this on-demand webcast from a live symposium, experts Komal Jhaveri, MD, FACP; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, discuss how they apply current clinical evidence to develop personalized treatment plans for HR-positive/HER2-negative early and advanced breast cancer, including the use of current and emerging targeted therapies and strategies to promote patient adherence.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 10, 2022

Expiration: June 09, 2023

No longer available for credit.

Share

Faculty

Komal Jhaveri

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Erica Mayer

Erica Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Laura M. Spring

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Lilly

Novartis Pharmaceuticals Corporation

Sanofi Genzyme

Target Audience

This program is intended for medical oncologists, pathologists, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan risk-adapted adjuvant treatment strategies for patients with early-stage HR-positive/HER2-negative breast cancer based on available evidence and use of risk assessment algorithms, cellular proliferation biomarkers, and multigene assays
  • Select individualized treatment for patients with HR-positive/HER2-negative metastatic breast cancer based on the available evidence, guidelines, tumor characteristics, patient preferences, and expert guidance
  • Apply appropriate strategies to increase medication adherence rates in breast cancer patients to improve outcomes and mitigate medication resistance

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Komal Jhaveri, MD, FACP, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Biotheranostics, Blueprint Medicines, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Genentech, Jounce Therapeutics, Lilly, Novartis, Pfizer, Seattle Genetics, SunPharma, and Taiho Oncology and funds for research support paid to her institution from ADC Therapeutics, AstraZeneca, Clovis Oncology, Debio, Genentech, Immunomedics/Gilead, Lilly, Merck/VelosBio, Novartis, Novita Pharmaceuticals, Pfizer, Puma, and Zymeworks.

Faculty Disclosure

Primary Author

Erica Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Erica L. Mayer, MD, MPH, has disclosed that she has received consulting fees from AstraZeneca, Gilead, Lilly, and Novartis.

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Laura M. Spring, MD, has disclosed that she has received consultant/advisor fees from Novartis and Puma and funds for research support paid to her institution from Merck and Phillips.

Staff Disclosure

Staff

Kelly Brandt, PharmD

Kelly G. Brandt, PharmD, BCOP, BCPS, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 10, 2022, through June 09, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and competence of learners to select and integrate new and emerging therapies into individualized treatment plans for HR-positive/HER2-negative breast cancer.